Get the Stockscreener App
8.15
0.74%
0.06
Pharming Group N V Adr stock is traded at $8.15, with a volume of 2,847.
It is up +0.74% in the last 24 hours and down -7.75% over the past month.
Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.
See More
Previous Close:
$8.09
Open:
$8.84
24h Volume:
2,847
Relative Volume:
0.48
Market Cap:
$547.14M
Revenue:
$277.56M
Net Income/Loss:
$-13.33M
P/E Ratio:
-42.89
EPS:
-0.19
Net Cash Flow:
$-6.54M
1W Performance:
+1.88%
1M Performance:
-7.75%
6M Performance:
-8.53%
1Y Performance:
-18.50%
1-Day Range:
$8.09
$8.84
1-Week Range:
$8.02
$8.84
52-Week Range:
$6.65
$11.07
Pharming Group N V Adr Stock (PHAR) Company Profile
Compare PHAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAR
Pharming Group N V Adr
|
8.15 | 547.14M | 277.56M | -13.33M | -6.54M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharming Group N V Adr Stock (PHAR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | Jefferies | Buy |
Pharming Group N V Adr Stock (PHAR) Latest News
Pharming Group to participate in March investor conference - GlobeNewswire Inc.
Pharming Group (OTCMKTS:PHGUF) Shares Cross Above 50 Day Moving Average – Time to Sell? - Defense World
Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26% - Simply Wall St
Pharming Group stock gains on KL1333’s blockbuster potential, says RBC - Investing.com India
H.C. Wainwright reiterates Buy on Pharming stock, pediatric trial shows safety and tolerability - Investing.com India
Jefferies initiates Pharming Group shares with Buy on revenue growth - Investing.com India
Oppenheimer cuts Pharming Group stock target, Outperform on Q3 results - Investing.com India
Earnings call: Pharming Group NV reports growth amid CEO transition - Investing.com
Earnings call: Pharming Group NV sees robust growth in Q3, CEO to step down - Investing.com
October 2024's Promising Penny Stocks to Watch - Yahoo Finance
Novavax (NVAX) Moves 19.2% Higher: Will This Strength Last? - Yahoo Finance
RGC Stock Quote Price and Forecast - CNN
Why Earnings Season Could Be Great for Pharming Group (PHAR) - Yahoo Finance
Can Pharming Group N.V. Sponsored ADR (PHAR) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Are Medical Stocks Lagging Lantheus (LNTH) This Year? - Nasdaq
Pharming Group (PHAR) - Zacks Investment Research
PHARM Stock Price and Chart — EURONEXT:PHARM - TradingView
Pharming Group N V Adr Stock (PHAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):